DAVID GREEN - 28 Feb 2023 Form 4 Insider Report for Biostage, Inc. (BSTG)

Role
CEO as of 2/28/2023, Director
Signature
/s/ Joseph Damasio, by power of attorney
Issuer symbol
BSTG
Transactions as of
28 Feb 2023
Transactions value $
$0
Form type
4
Filing time
02 Mar 2023, 19:00:39 UTC
Previous filing
27 Jan 2023
Next filing
28 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSTG Stock Option (right to buy) Award $0 +39,662 $0.000000 39,662 28 Feb 2023 Common Stock, par value $0.01 per share 39,662 $6.00 Direct F1
transaction BSTG Stock Option (right to buy) Award $0 +38,773 $0.000000 38,773 28 Feb 2023 Common Stock, par value $0.01 per share 38,773 $6.00 Direct F2
transaction BSTG Stock Option (right to buy) Award $0 +732,384 $0.000000 732,384 28 Feb 2023 Common Stock, par value $0.01 per share 732,384 $6.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant was fully exercisable as of date of grant.
F2 The non-qualified stock option was scheduled to vest during the twelve months following the grant date, but in connection with the Issuer's transition to a new CEO as of March 1, 2023, this option has been forfeited.
F3 The non-qualified stock option was scheduled to vest monthly in thirty-six equal monthly installments on each monthly anniversary of February 28, 2023, but in connection with the Issuer's transition to a new CEO as of March 1, 2023, 488,256 shares underlying this option have been forfeited, and subject to the Reporting Person's execution of a customary release, the remaining 244,128 shares will be deemed fully vested and exercisable.